Skip to main content
Premium Trial:

Request an Annual Quote

Marina Buys Novosom Delivery Technology for $5M in Stock

Premium

Marina Biotech, formerly MDRNA, said this week that it has acquired certain drug-delivery intellectual property from Novosom for roughly $5 million in stock.

Specifically, Marina has picked up the rights to Novosom's Smarticle technology, a liposome-based delivery vehicle applicable for both systemic and local siRNA administration, the company said. It is covered by 42 issued or allowed patents and 31 pending patent applications worldwide.

Additional terms of the transaction were not disclosed.

"We believe that this technology and intellectual property estate, resulting from years of hard work and diligent IP prosecution on the part of Novosom, is a significant addition to our existing RNA delivery platforms and … IP estate," Marina President and CEO Michael French said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.